Rocket Pharmaceuticals Rule 144 Notice — Insider Disposed 8,099 Shares, Plans Additional Sale

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. (RCKT) notice reports proposed and recent insider transactions under Rule 144. An individual will offer 361 common shares held from a restricted stock vesting on 08/15/2025; the aggregate market value of the proposed sale is $1,081.63 and the shares are expected to be sold on 08/19/2025 on NASDAQ. The filing also discloses three prior sales by the same person during the past three months totaling 8,099 common shares for combined gross proceeds of $25,704.49. The filer attests they are unaware of any undisclosed material adverse information about the issuer.

Positive

• None.

Negative

• Insider sales totaling 8,099 shares for $25,704.49 in the past three months could attract investor attention despite being small relative to outstanding shares
• Planned immediate sale of 361 vested restricted shares indicates further insider disposition in the near term

Insights

Securities Analyst

Insider sold a small number of shares; transactions appear routine and immaterial to market capitalization.

The disclosed sales — 8,099 shares for $25,704.49 over the past three months plus a planned sale of 361 vested shares valued at $1,081.63 — represent a vanishingly small fraction of the issuer's outstanding common stock (107,903,871 shares). From a market-impact perspective, these transactions are unlikely to affect share price or indicate major insider liquidity events. The origin of the planned sale is restricted stock vesting, which is a typical form of employee compensation and subsequent disposition.

Corporate Governance Expert

Disclosure complies with Rule 144 norms; no governance red flags evident from the notice alone.

The filer provided required details including acquisition date, nature of acquisition (restricted stock vesting), and sales history. The signature attestation regarding material nonpublic information is included. There is no indication of unusual timing, related-party transfers, or concentrated block sales that would raise governance concerns. Absent other context, these are routine insider disposition disclosures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	361	1081.63	107903871	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			361	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Militello 9 Cedarbrook Drive Cranbury RI 08512	Common	05/20/2025	357	2301.22
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/14/2025	7043	21260.70
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/18/2025	699	2142.57

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transactions does the RCKT Form 144 disclose?

The notice discloses prior sales of 8,099 common shares for $25,704.49 in the past three months and a proposed sale of 361 vested shares valued at $1,081.63.

What was the source of the shares being sold under Rule 144 for RCKT?

The shares subject to the proposed sale were acquired via restricted stock vesting on 08/15/2025 and are described as compensation.

On which exchange will the planned RCKT sale occur and when?

The planned sale is expected to take place on NASDAQ on 08/19/2025.

How large are these transactions relative to Rocket Pharmaceuticals' outstanding shares?

The issuer reports 107,903,871 shares outstanding; the disclosed recent sales and proposed sale represent a negligible percentage of total shares outstanding.

Does the Form 144 include an attestation about material nonpublic information?

Yes; the filer signs a representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.

Were any of the disclosed sales gifts or other nonstandard transfers?

No; the filing shows prior sales and the newly acquired shares were vested compensation, with no gift indicated.